ArticleJournal of cardiothoracic surgery2025
CYBB identified as a key immune hub gene linking lung cancer and atrial fibrillation.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe proportion of patients with lung cancer complicated by atrial fibrillation (AF) is increasing. Identifying shared molecular targets between these two conditions may provide important prognostic insights for patients with comorbidities.
methodsThe GSE8569 and GSE41177 datasets were downloaded from the Gene Expression Omnibus (GEO) database. Differential expression analysis was performed using the limma package in R. Weighted gene co-expression network analysis (WGCNA) was conducted to identify significant gene modules. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, along with gene set enrichment analysis (GSEA), were used to explore biological functions. Clinical survival data for lung cancer were obtained from The Cancer Genome Atlas (TCGA), and receiver operating characteristic (ROC) analysis was conducted using the R package ROC (version 1.17.0.1).
resultsA total of 598 differentially expressed genes (DEGs) were identified. These DEGs were primarily enriched in cell proliferation, inflammatory responses, non-small cell lung cancer, the p53 signaling pathway, and the cell cycle. Three core genes (CYBB, ITGB2, FCER1G) were identified. Notably, CYBB was downregulated in lung cancer compared to normal tissue. Patients in the low-risk group had significantly better survival outcomes. Heatmap visualization showed that expression of CYBB decreased with increasing risk scores, suggesting a protective role.
conclusionCYBB expression may influence lung cancer prognosis and contribute to the pathogenesis of AF. Further research is needed to clarify CYBB's role in patients with both conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.